Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.21 which represents a slight increase of $1.36 or 4.41% from the prior close of $30.85. The stock opened at $31.29 and ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Amazon acquired primary care provider One Medical for $3.9 billion in 2022, and fills prescriptions through Amazon One ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares were up 6.6% during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $28.00 to $38.00.

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective increased by equities research analysts at Canaccord Genuity Group from $28.00 to $38.00 in a report released on ...

Finding the right treatment for erectile dysfunction (ED) can feel overwhelming with so many options out there! Rugiet, ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic ...

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.